99�Ⱦò������µ�ַ

How to boost immune response to vaccines in older people

Key points:

• Identifying interventions that improve vaccine efficacy in older persons is a global challenge to deliver healthy ageing for an increasing ageing population.
• The Linterman lab has identified a route for counteracting the age-related loss of two key immune cell types, which are important for antibody generation and the development of immunological memory.
• After this validation in mice, the findings offer an attractive intervention to tailor the make-up of vaccines for older people.

Research just published by the Linterman lab shows that the immune system of older mice can be given a helping hand by applying immunology expertise and some genital wart treatment (don’t try this at home just yet)!

Mice and humans show similar age-dependent changes in their immune system so this finding offers hope for easily increasing the robustness of vaccination response in the older population.

As we age, the function of our immune system declines, rendering us more susceptible to infections, and making us less able to generate protective immunity after vaccination. By understanding the cellular and molecular mechanisms that underpin this poor response in older individuals, researchers in the Linterman lab were able to repurpose an existing treatment for genital warts, and demonstrate that this was effective in overcoming the age-related effects on two of the many cell types making up our immune system. The research is published online in the journal .

Dr Michelle Linterman, a group leader in the Institute’s Immunology research programme, said: “The current coronavirus pandemic highlights that older members of our families and communities are more susceptible to the morbidity and mortality associated with infectious diseases. Therefore, it is imperative that we understand how the immune system in older people works, and to explore how we might be able to boost their immune responses to vaccines to ensure they work well in this vulnerable part of our society.”

Vaccines work by generating antibodies that are able to block the ability of pathogens to infect us. Antibody secreting cells are produced in the germinal centre, immune reaction hubs that forms after infection or vaccination. With age, the magnitude and quality of the germinal centre reaction declines.

Immune cells called T follicular helper cells are essential to the germinal centre response. In this study the team used mice and humans to investigate why T follicular helper cell numbers decline with age, and if there is a way to boost them upon vaccination.

“The germinal centre response is a highly collaborative process that requires multiple cell types to interact at the right place and the right time. Therefore, it made sense to us that defects in one or more of these cell types could explain the poor germinal centre response observed in older individuals after vaccination,” explains Dr Linterman.

The researchers found that older mice and humans form fewer T follicular helper cells after vaccination, which is linked with a poor germinal centre response and antibody response. By developing our understanding of the cellular and molecular events occurring in the germinal centre after vaccination, the researchers identified that T follicular helper cells in older mice and people received less stimulatory interactions from their immune system co-workers.  By using a cream (imiquimod, currently used to treat genital warts in humans) on the site of immunisation to boost the number of stimulatory cells, they were able to restore the formation of T follicular helper cells in older mice and also rescue the age-dependent defects in another immune cell type (dendritic cells). Encouragingly, this demonstrates that the age-related defects in T follicular helper cell formation in ageing are not irreversible, and can be overcome therapeutically.

The full picture and evaluation of whether this approach will work as an intervention in humans requires more research into why the germinal centre response changes with age, and what can be done to overcome this. Once achieved, it could be that clinical trials are established to incorporate this knowledge into new vaccine formulations for older people.

Notes to Editors

Publication reference

Stebegg & Bignon et al. . eLife 2020;9:e52473 doi: 10.7554/eLife.52473

Press contact

Dr Louisa Wood, Communications Manager, louisa.wood@babraham.ac.uk

Image description

A comparison of mouse lymph nodes from young (left) and aged (right) mice fourteen days after immunisation. B cell follicles are shown in yellow (IgD) and proliferating germinal centre cells (Blue, Ki67) are shown within the B cell follicle. T cells are shown in green.

Affiliated authors (in author order):

Marisa Stebegg – visiting scientist, Linterman group

Alexandre Bignon – previous postdoctoral researcher, Linterman group

Danika Hill – research fellow, Linterman group

Alyssa Silva-Cayetano – PhD student, Linterman group

Christel Krueger – bioinformatician (Epigenetics), Bioinformatics facility

Ine Vanderleyden – postdoctoral researcher, Linterman group

Silvia Innocentin – research assistant, Linterman group

James Dooley – senior staff scientist, Liston group

Jonathan Clark – Head of the Biological Chemistry facility

Adrian Liston – group leader, Immunology research  programme

Edward Carr – clinical lecturer, Linterman group

Michelle Linterman – group leader, Immunology research  programme

Research funding

This study was supported by funding from the Biotechnology and Biological Sciences Research Council, the European Research Council (TWILIGHT), and the European Union’s Horizon 2020 research and innovation programme “ENLIGHT-TEN” under the Marie Skłodowska-Curie grant agreement No.: 675395.

Additional/related resources:

News 4 June 2019 Could boosting the gut microbiome be the secret to healthier older age?

News 19 October 2016 Institute applies research expertise to meet global developmental challenges

News 17 March 2016 Understanding immune cell biology to improve vaccination response

Animal research statement

As a publicly funded research institute, the 99�Ⱦò������µ�ַ is committed to engagement and transparency in all aspects of its research. The research presented here used mice that were immunised by injection and then humanely killed to allow researchers to analyse immune cell numbers and use those to assess the animals’ immune response to vaccines.

Please follow the link for further details of our .

About the 99�Ⱦò������µ�ַ

The 99�Ⱦò������µ�ַ undertakes world-class life sciences research to generate new knowledge of biological mechanisms underpinning ageing, development and the maintenance of health. Our research focuses on cellular signalling, gene regulation and the impact of epigenetic regulation at different stages of life. By determining how the body reacts to dietary and environmental stimuli and manages microbial and viral interactions, we aim to improve wellbeing and support healthier ageing. The Institute is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation, through an Institute Core Capability Grant and also receives funding from other UK research councils, charitable foundations, the EU and medical charities.